Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Minimally invasive suturing for vascular bore closure and heart defect repair

Descrizione del progetto

Un dispositivo di chiusura vascolare di grandi dimensioni più sicuro

I notevoli progressi delle tecnologie mediche hanno consentito lo sviluppo di procedure transcatetere in sostituzione degli interventi a cuore aperto. Queste procedure consentono di ottenere risultati clinici migliori, degenze ospedaliere più brevi e tempi di ripresa più rapidi, ma richiedono ampie zone di accesso nei vasi. La chiusura di queste ampie zone di accesso è associata a un alto tasso di complicanze. Il progetto NVCD, finanziato dal CEI, svilupperà una tecnologia proprietaria di microsutura per ottenere una chiusura vascolare di grandi dimensioni più efficiente e sicura. A seguito dello sviluppo del prototipo e della convalida preclinica, il progetto condurrà sperimentazioni cliniche per ottenere la certificazione CE per la distribuzione commerciale del dispositivo di sutura.

Obiettivo

Cardiovascular diseases (CVDs) remain a major health problem worldwide and a leading cause of mortality, with over annual 18 million deaths. In Europe, CVDs are associated with 4 million deaths and costs of around 210 billion per year.
Many surgeries to treat cardiac conditions are shifting to be minimally invasive and this is a trend expected to continue growing due to its multiple advantages over open interventions. However, as newly developed devices for transcatheter procedures become bigger they also require larger vascular access sites. A couple of devices are used in vascular large-bore closure (e.g. ProGlide from Abbott). However, they are associated with still high vascular and bleeding complications (up to 20%, depending on the operators skills). Such complications are linked to longer hospitalizations, unnecessary suffering, and greater healthcare costs (20k per patient), as well as higher morbidity and mortality.
To solve this persistent unmet need in the field of cardiovascular surgery, Novelrad has specifically developed the NVCD closure device. It integrates a proprietary and revolutionary micro-suturing technology that mimics the standard surgical technique, effectively delivering a multipoint continuous suture in a minimally invasive manner. The NVCD is easy to use and enables a safer closure of large bores, potentially reducing complication rates to 3%, saving up to 15 min in the procedure, and bringing important cost savings related to same-day discharge and complications management. Importantly, with a single NVCD device large and extra-large bore closure of veins and arteries is possible (up to 30Fr).
After obtaining a fully functional prototype of the NVCD and advancing in pre-clinical tests, we now aim to perform a first-in-human (FIH) study and complete the clinical trial required to obtain its CE certification as a Class III medical device. This will be crucial to prepare for industrialization and commercial deployment in Europe and globally.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-EIC-2023-ACCELERATOR-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

NOVELRAD LTD
Contributo netto dell'UE
€ 2 499 999,00
Indirizzo
KIBBUTZ METZER
3882000 METZER
Israele
PMI
Sì
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 4 121 068,75